Antibody Drug May Protect Nursing Home Residents, Staff From COVID-19
FRIDAY, Jan. 22, 2021 -- An antibody drug that has emergency use authorization from the U.S. Food and Drug Administration for use in early-stage COVID-19 patients with symptoms prevented COVID-19 infections in nursing residents and staff who were exposed to the virus, a new study shows.
It was conducted to find out if bamlanivimab could protect nursing home residents and staff against infections with the new coronavirus, The New York Times reported. In the study, mobile labs and medical workers were sent to nursing homes immediately after a single infection was detected, and temporary infusion centers were set up to administer the drug.
The study included 299 residents and 666 staff. Some received the drug and others were given a placebo. Compared with those who received placebo, rates of symptomatic infections were 80 percent lower among residents and 60 percent lower among staff who received the drug, The Times reported.
The preliminary results of the study conducted by drug maker Eli Lilly have not been peer-reviewed or published. The company said it expects to present the results at a medical meeting and to publish them in a peer-reviewed journal but provided no timeline, The Times reported.
© 2021 HealthDay. All rights reserved.
Posted: January 2021
Further Support and Information on COVID-19
Read this next
FRIDAY, March 5, 2021 -- Three main modes of transmission have been identified for giardiasis outbreaks in the United States in 2012 to 2017, although a single transmission mode...
FRIDAY, March 5, 2021 -- The frequency of urgent or emergent vitreoretinal surgical procedures decreased during the COVID-19 pandemic, according to a study published online March...
FRIDAY, March 5, 2021 -- Twelve cases of delayed large local reactions to the mRNA-1273 vaccination against severe acute respiratory syndrome coronavirus 2 are described in a...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.